{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:42:39Z","timestamp":1761964959370,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["12\/206\/09"],"award-info":[{"award-number":["12\/206\/09"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2453-6","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T13:38:25Z","timestamp":1517837905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0739-3412","authenticated-orcid":false,"given":"Matthew","family":"Hammond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan B.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony P.","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin R.","family":"Chilvers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William Duncan","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Livermore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Parfrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Marie","family":"Swart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Stirling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Thickett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moira","family":"Whyte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"issue":"6","key":"2453_CR1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1136\/thx.2010.148031","volume":"66","author":"V Navaratnam","year":"2011","unstructured":"Navaratnam V, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66(6):462\u20137.","journal-title":"Thorax"},{"key":"2453_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2377-11-38","volume":"11","author":"KJ Macpherson","year":"2011","unstructured":"Macpherson KJ, et al. Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986\u20132005: a retrospective cohort study. BMC Neurol. 2011;11:38.","journal-title":"BMC Neurol"},{"issue":"2","key":"2453_CR3","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, et al. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3\u201319.","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"2453_CR4","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"G Raghu","year":"2012","unstructured":"Raghu G, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968\u201377.","journal-title":"N Engl J Med"},{"issue":"21","key":"2453_CR5","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMoa042976","volume":"353","author":"M Demedts","year":"2005","unstructured":"Demedts M, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"2453_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3109\/15412555.2011.630248","volume":"9","author":"T Ringbaek","year":"2012","unstructured":"Ringbaek T, Martinez G, Lange P. A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation. COPD. 2012;9(1):12\u20135.","journal-title":"COPD"},{"issue":"1","key":"2453_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","volume":"186","author":"I Noth","year":"2012","unstructured":"Noth I, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186(1):88\u201395.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9779","key":"2453_CR8","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760\u20139.","journal-title":"Lancet"},{"issue":"22","key":"2453_CR9","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King Jr TE, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"12","key":"2453_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079\u201387.","journal-title":"N Engl J Med"},{"issue":"22","key":"2453_CR11","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"key":"2453_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12916-016-0558-x","volume":"14","author":"B Rochwerg","year":"2016","unstructured":"Rochwerg B, et al. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med. 2016;14:18.","journal-title":"BMC Med"},{"issue":"2","key":"2453_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/thoraxjnl-2012-202403","volume":"68","author":"L Shulgina","year":"2013","unstructured":"Shulgina L, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68(2):155\u201362.","journal-title":"Thorax"},{"key":"2453_CR14","doi-asserted-by":"crossref","unstructured":"Molyneaux PL, Cox MJ, Mallia P, Johnston SL, Moffatt MF, Cookson WOC, Maher TM. The role of the respiratory microbiome in idiopathic pulmonary fibrosis. Thorax. 2013;68 Suppl 3:A22.","DOI":"10.1136\/thoraxjnl-2013-204457.45"},{"key":"2453_CR15","unstructured":"National Institute for Health and Care Excellence (2013). Idiopathic pulmonary fibrosis in adults: diagnosis and management. NICE guideline (CG163). https:\/\/www.nice.org.uk\/corporate\/ecd1\/chapter\/referencing-and-citations ."},{"issue":"3","key":"2453_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/occmed\/kqm162","volume":"58","author":"C Stenton","year":"2008","unstructured":"Stenton C, The MRC. Breathlessness Scale. Occup Med. 2008;58(3):226\u20137.","journal-title":"Occup Med"},{"issue":"6","key":"2453_CR17","first-page":"659","volume":"123","author":"RO Crapo","year":"1981","unstructured":"Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981;123(6):659\u201364.","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"2453_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","volume":"177","author":"TE King Jr","year":"2008","unstructured":"King Jr TE, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(1):75\u201381.","journal-title":"Am J Respir Crit Care Med"},{"key":"2453_CR19","doi-asserted-by":"publisher","first-page":"g6196","DOI":"10.1136\/bmj.g6196","volume":"349","author":"M Fralick","year":"2014","unstructured":"Fralick M, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ. 2014;349:g6196.","journal-title":"BMJ"},{"issue":"4","key":"2453_CR20","doi-asserted-by":"publisher","first-page":"296","DOI":"10.7326\/0003-4819-119-4-199308150-00008","volume":"119","author":"H Velazquez","year":"1993","unstructured":"Velazquez H, et al. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119(4):296\u2013301.","journal-title":"Ann Intern Med"},{"key":"2453_CR21","doi-asserted-by":"crossref","unstructured":"Patel AS, Siegert R, Brignall K, Keir G, Bajwah S, Desai SR, Wells AU, Higgison IJ, Birring SS. The assessment of health related quality of life in interstitial lung disease with the King\u2019s Brief Interstitial Lung Disease questionnaire (K-BILD). Thorax. 2011;66:A61.","DOI":"10.1136\/thoraxjnl-2011-201054b.133"},{"key":"2453_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-0-387-78665-0_5","volume-title":"Handbook of disease burdens and quality of life measures","author":"N Gusi","year":"2010","unstructured":"Gusi N, Olivares PR, Rajendram R. The EQ-5D Health-Related Quality of Life Questionnaire. In: Preedy VR, Watson RR, editors. Handbook of disease burdens and quality of life measures. New York: Springer New York; 2010. p. 87\u201399."},{"issue":"2","key":"2453_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319\u201338.","journal-title":"Eur Respir J"},{"issue":"4","key":"2453_CR24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1183\/09031936.05.00034905","volume":"26","author":"N Macintyre","year":"2005","unstructured":"Macintyre N, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720\u201335.","journal-title":"Eur Respir J"},{"issue":"4","key":"2453_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1164\/rccm.201011-1790OC","volume":"184","author":"RM Bois du","year":"2011","unstructured":"du Bois RM, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459\u201366.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2453_CR26","first-page":"102","volume":"28","author":"SH Lee","year":"2011","unstructured":"Lee SH, et al. Prognostic factors for idiopathic pulmonary fibrosis: clinical, physiologic, pathologic, and molecular aspects. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):102\u201312.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6 Pt 1","key":"2453_CR27","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1164\/ajrccm.152.6.8520747","volume":"152","author":"Y Honda","year":"1995","unstructured":"Honda Y, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med. 1995;152(6 Pt 1):1860\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3 Pt 1","key":"2453_CR28","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1164\/ajrccm.162.3.9910080","volume":"162","author":"H Takahashi","year":"2000","unstructured":"Takahashi H, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162(3 Pt 1):1109\u201314.","journal-title":"Am J Respir Crit Care Med"},{"key":"2453_CR29","doi-asserted-by":"crossref","unstructured":"Rosas IO, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med\/Pub Lib Sci. 2008;5(4):623\u201333.","DOI":"10.1371\/journal.pmed.0050093"},{"issue":"8","key":"2453_CR30","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.5858\/2009-0144-OA.1","volume":"134","author":"S Fujishima","year":"2010","unstructured":"Fujishima S, et al. Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis. Arc Pathol Lab Med. 2010;134(8):1136\u201342.","journal-title":"Arc Pathol Lab Med"},{"issue":"5","key":"2453_CR31","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1378\/chest.11-2735","volume":"143","author":"JW Song","year":"2013","unstructured":"Song JW, et al. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013;143(5):1422\u20139.","journal-title":"Chest"},{"issue":"1","key":"2453_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1183\/09031936.98.11010120","volume":"11","author":"H Yamanouchi","year":"1998","unstructured":"Yamanouchi H, et al. Neutrophil elastase: alpha-1-proteinase inhibitor complex in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis. Eur Respir J. 1998;11(1):120\u20135.","journal-title":"Eur Respir J"},{"issue":"6","key":"2453_CR33","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1183\/09031936.00127011","volume":"40","author":"A Takemasa","year":"2012","unstructured":"Takemasa A, Ishii Y, Fukuda T. A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice. Eur Respir J. 2012;40(6):1475\u201382.","journal-title":"Eur Respir J"},{"issue":"3","key":"2453_CR34","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1164\/ajrccm.159.3.9805060","volume":"159","author":"L Lammi","year":"1999","unstructured":"Lammi L, et al. Type III and type I procollagen markers in fibrosing alveolitis. Am J Respir Crit Care Med. 1999;159(3):818\u201323.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2453_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/rheumatology\/34.1.31","volume":"34","author":"S Kuroki","year":"1995","unstructured":"Kuroki S, et al. Determination of various cytokines and type III procollagen aminopeptide levels in bronchoalveolar lavage fluid of the patients with pulmonary fibrosis: inverse correlation between type III procollagen aminopeptide and interferon-gamma in progressive patients. Br J Rheumatol. 1995;34(1):31\u20136.","journal-title":"Br J Rheumatol"},{"issue":"6","key":"2453_CR36","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1164\/ajrccm.162.6.2003049","volume":"162","author":"AG Nicholson","year":"2000","unstructured":"Nicholson AG, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Ame J Respir Crit Care Med. 2000;162(6):2213\u20137.","journal-title":"Ame J Respir Crit Care Med"},{"issue":"10","key":"2453_CR37","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1164\/rccm.201201-0006PP","volume":"185","author":"G Raghu","year":"2012","unstructured":"Raghu G, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185(10):1044\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"2453_CR38","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1136\/thoraxjnl-2012-202580","volume":"67","author":"AU Wells","year":"2012","unstructured":"Wells AU, et al. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax. 2012;67(11):938\u201340.","journal-title":"Thorax"},{"issue":"2","key":"2453_CR39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.rmed.2013.11.007","volume":"108","author":"CP Atkins","year":"2013","unstructured":"Atkins CP, Loke YK, Wilson AM. Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials. Respir Med. 2013;108(2):376\u201387.","journal-title":"Respir Med"},{"issue":"7","key":"2453_CR40","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1002110","volume":"363","author":"DA Zisman","year":"2010","unstructured":"Zisman DA, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620\u20138.","journal-title":"N Engl J Med"},{"key":"2453_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","volume":"113","author":"L Richeldi","year":"2016","unstructured":"Richeldi L, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials. Respir Med. 2016;113:74\u20139.","journal-title":"Respir Med"},{"issue":"8","key":"2453_CR42","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.rmed.2012.04.008","volume":"106","author":"H M\u00fcllerova","year":"2012","unstructured":"M\u00fcllerova H, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124\u201333.","journal-title":"Respir Med"},{"issue":"8","key":"2453_CR43","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1136\/thx.2008.110445","volume":"64","author":"AG Richter","year":"2009","unstructured":"Richter AG, et al. Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis. Thorax. 2009;64(8):692\u20137.","journal-title":"Thorax"},{"issue":"3","key":"2453_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1469-0691.2005.01337.x","volume":"12","author":"S Vidal","year":"2006","unstructured":"Vidal S, et al. Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin Microbiol Infect. 2006;12(3):231\u20135.","journal-title":"Clin Microbiol Infect"},{"key":"2453_CR45","first-page":"A3769","volume":"187","author":"MK Han","year":"2013","unstructured":"Han MK, Erb-Downward J, Zhou Y, Tayob N, Murray S, Flaherty KR, Huffnagle GB, Martinez FJ. The IPF microbiome: analysis from the COMET study. Am J Respir Crit Care Med. 2013;187:A3769.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2453_CR46","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.137.4.1305","volume":"137","author":"L Harvath","year":"1986","unstructured":"Harvath L, Yancey KB, Katz SI. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. J Immunol. 1986;137(4):1305\u201311.","journal-title":"J Immunol"},{"issue":"5","key":"2453_CR47","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/j.1365-2133.2005.06559.x","volume":"152","author":"T Suda","year":"2005","unstructured":"Suda T, et al. Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner. Br J Dermatol. 2005;152(5):887\u201395.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2453_CR48","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1128\/AAC.17.3.322","volume":"17","author":"R Anderson","year":"1980","unstructured":"Anderson R, et al. Effects of sulfamethoxazole and trimethoprim on human neutrophil and lymphocyte functions in vitro: in vivo effects of co-trimoxazole. Antimicrob Agents Chemother. 1980;17(3):322\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2453_CR49","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/jac\/10.6.505","volume":"10","author":"JP Siegel","year":"1982","unstructured":"Siegel JP, Remington JS. Effect of antimicrobial agents on chemiluminescence of human polymorphonuclear leukocytes in response to phagocytosis. J Antimicrob Chemother. 1982;10(6):505\u201315.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2453_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1128\/AAC.20.1.15","volume":"20","author":"WD Welch","year":"1981","unstructured":"Welch WD, Davis D, Thrupp LD. Effect of antimicrobial agents on human polymorphonuclear leukocyte microbicidal function. Antimicrob Agents Chemother. 1981;20(1):15\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2453_CR51","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1172\/JCI113005","volume":"79","author":"AM Cantin","year":"1987","unstructured":"Cantin AM, et al. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest. 1987;79(6):1665\u201373.","journal-title":"J Clin Invest"},{"issue":"5","key":"2453_CR52","doi-asserted-by":"publisher","first-page":"L805","DOI":"10.1152\/ajplung.00009.2009","volume":"297","author":"VM Felton","year":"2009","unstructured":"Felton VM, Borok Z, Willis BC. N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol. 2009;297(5):L805\u201312.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"5","key":"2453_CR53","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1365-2362.2006.01636.x","volume":"36","author":"K Psathakis","year":"2006","unstructured":"Psathakis K, et al. Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis. Eur J Clin Invest. 2006;36(5):362\u20137.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2453_CR54","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1164\/ajrccm\/144.1.146","volume":"144","author":"J Behr","year":"1991","unstructured":"Behr J, et al. Pathogenetic significance of reactive oxygen species in diffuse fibrosing alveolitis. Am Rev Respir Dis. 1991;144(1):146\u201350.","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"2453_CR55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJM198401193100304","volume":"310","author":"RG Crystal","year":"1984","unstructured":"Crystal RG, et al. Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). N Engl J Med. 1984;310(3):154\u201366.","journal-title":"N Engl J Med"},{"issue":"2","key":"2453_CR56","first-page":"138","volume":"20","author":"KM Beeh","year":"2003","unstructured":"Beeh KM, et al. Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(2):138\u201343.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"2453_CR57","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1378\/chest.07-1948","volume":"133","author":"BW Kinder","year":"2008","unstructured":"Kinder BW, et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest. 2008;133(1):226\u201332.","journal-title":"Chest"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2453-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T21:23:26Z","timestamp":1693517006000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2453-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2453"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2453-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"7 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Surrey Borders Research Ethics Committee (reference 14\/LO\/1800) has approved the trial at all participating centres. Participant consent is obtained prior to any trial-related procedure. During the consent process it is made clear that the participant can decline to participate in all or any aspect of the trial, at any time and for any reason, without affecting their future care or treatment. Patients unable to provide written informed consent are deemed ineligible for the trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors of this paper have no financial or other competing interests that impact on their responsibilities towards the scientific value or potential publishing activities associated with the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"89"}}